Sigal Fattal
Director of Finance/CFO chez CHEMOMAB THERAPEUTICS LTD.
Fortune : 584 $ au 31/03/2024
Profil
Sigal Fattal is currently the Chief Financial Officer at Chemomab Therapeutics Ltd.
She previously held the position of Chief Financial Officer & Executive Vice President at TransPharma Medical Ltd.
From 2013 to 2016, she served as the Chief Financial Officer at Evogene Ltd.
Additionally, from 2017 to 2019, she was the Chief Financial Officer at BiomX Ltd.
Ms. Fattal obtained her undergraduate degree and MBA from Tel-Aviv University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/03/2024 | 15 002 ( 0,01% ) | 584 $ | 31/03/2024 |
Postes actifs de Sigal Fattal
| Sociétés | Poste | Début |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Director of Finance/CFO | 01/06/2023 |
Anciens postes connus de Sigal Fattal
| Sociétés | Poste | Fin |
|---|---|---|
BiomX Ltd.
 BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Director of Finance/CFO | 01/12/2019 |
| EVOGENE LTD. | Director of Finance/CFO | 01/01/2016 |
TransPharma Medical Ltd.
 TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Director of Finance/CFO | - |
Formation de Sigal Fattal
| Tel-Aviv University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| EVOGENE LTD. | Health Technology |
| CHEMOMAB THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
BiomX Ltd.
BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Health Technology |
